Back to Search
Start Over
Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
- Source :
-
Respirology (Carlton, Vic.) [Respirology] 2015 Apr; Vol. 20 (3), pp. 389-94. Date of Electronic Publication: 2015 Feb 26. - Publication Year :
- 2015
-
Abstract
- Idiopathic pulmonary fibrosis (IPF) is an incurable condition that is characterized by progressive pulmonary fibrosis, architectural distortion of the lung and loss of gas exchange units. Until recently, there was no effective treatment for this condition. However, there were two landmark trials published earlier this year, which have changed the management of this condition. Pirfenidone (Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis trial) and nintedanib (Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis-1 and -2 trials) have both demonstrated positive outcomes in patients with IPF. In this perspective, we critically discuss the role of these agents in IPF and in the broader pulmonary fibrosis population.<br /> (© 2015 Asian Pacific Society of Respirology.)
- Subjects :
- Antineoplastic Agents pharmacology
Clinical Trials as Topic
Disease Management
Disease Progression
Humans
Idiopathic Pulmonary Fibrosis diagnosis
Idiopathic Pulmonary Fibrosis metabolism
Idiopathic Pulmonary Fibrosis physiopathology
Treatment Outcome
Tumor Necrosis Factor-alpha antagonists & inhibitors
Idiopathic Pulmonary Fibrosis drug therapy
Indoles pharmacology
Lung pathology
Lung physiopathology
Pyridones pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1440-1843
- Volume :
- 20
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Respirology (Carlton, Vic.)
- Publication Type :
- Academic Journal
- Accession number :
- 25727967
- Full Text :
- https://doi.org/10.1111/resp.12484